We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$169B
| $1.3M | 1.03% |
16,421
+11,531
| +236% | +$937K |
|
27
Walmart Inc
WMT
$915B
| $1.28M | 1.02% |
+53,313
| New | +$1.29M |
|
28
United Therapeutics
UTHR
$22.5B
| $1.25M | 0.99% |
+10,566
| New | +$1.27M |
|
|
29
PUT
Procter & Gamble
PG
$353B
| $1.23M | 0.98% |
61,500
+46,500
| +310% | +$4.04M |
|
|
KITE
30
DELISTED
Kite Pharma, Inc.
KITE
| $1.18M | 0.94% |
+21,134
| New | +$1.18M |
|
31
Starbucks
SBUX
$124B
| $1.14M | 0.91% |
+21,100
| New | +$1.18M |
|
|
CMRX
32
DELISTED
Chimerix, Inc.
CMRX
| $1.14M | 0.9% |
205,266
-15,000
| -7% | -$68.7K |
|
33
General Mills
GIS
$20.7B
| $1.12M | 0.89% |
+17,506
| New | +$1.22M |
|
34
CALL
Sarepta Therapeutics
SRPT
$1.82B
| $1.1M | 0.87% |
173,300
+129,800
| +298% | +$3.92M |
|
35
CALL
Intuitive Surgical
ISRG
$142B
| $1.03M | 0.82% |
242,100
+147,600
| +156% | +$11.3M |
|
36
Five Below
FIVE
$10.9B
| $1M | 0.79% |
24,830
+10,135
| +69% | +$469K |
|
37
TJX Companies
TJX
$171B
| $966K | 0.77% |
+25,828
| New | +$1.01M |
|
38
Bank OZK
OZK
$5.8B
| $909K | 0.72% |
23,675
+21,175
| +847% | +$803K |
|
39
CALL
Regeneron Pharmaceuticals
REGN
$71.2B
| $777K | 0.62% |
47,000
+21,500
| +84% | +$8.62M |
|
|
AGN
40
DELISTED
Allergan plc
AGN
| $764K | 0.61% |
3,316
-722
| -18% | -$176K |
|
41
Meta Platforms (Facebook)
META
$1.69T
| $744K | 0.59% |
+5,800
| New | +$720K |
|
|
42
CALL
Apple
AAPL
$4.89T
| $691K | 0.55% |
194,400
+25,200
| +15% | +$667K |
|
|
WWAV
43
CALL
DELISTED
The WhiteWave Foods Company
WWAV
| $686K | 0.54% |
84,100
| – | – |
|
|
44
CALL
Biogen
BIIB
$30.8B
| $678K | 0.54% |
28,300
-8,900
| -24% | -$2.64M |
|
|
TSRO
45
PUT
DELISTED
TESARO, Inc.
TSRO
| $650K | 0.52% |
111,300
-50,100
| -31% | -$4.68M |
|
46
Coca-Cola
KO
$365B
| $633K | 0.5% |
+14,961
| New | +$656K |
|
|
AERI
47
DELISTED
Aerie Pharmaceuticals
AERI
| $628K | 0.5% |
+16,630
| New | +$367K |
|
48
IBM
IBM
$206B
| $623K | 0.49% |
4,106
+4,001
| +3,810% | +$607K |
|
49
CALL
NXP Semiconductors
NXPI
$68.3B
| $610K | 0.48% |
+56,600
| New | +$4.8M |
|
|
SAGE
50
DELISTED
Sage Therapeutics
SAGE
| $588K | 0.47% |
12,778
+4,005
| +46% | +$163K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.